key: cord-0710505-t1oy9fuo
authors: Proietti, I.; Mambrin, A.; Bernardini, N.; Tolino, E.; Balduzzi, V.; Maddalena, P.; Marchesiello, A.; Michelini, S.; Volpe, S.; Skroza, N.; Potenza, C.
title: Urticaria in an Infant with SARS‐CoV‐2 Positivity
date: 2020-07-22
journal: Dermatol Ther
DOI: 10.1111/dth.14043
sha: ec1d71fbc748adc0a650ec90863cacb58bf4b4fb
doc_id: 710505
cord_uid: t1oy9fuo

nan

COVID-19 occurs predominantly with respiratory symptoms such as cough and dyspnea in addition to fever, muscle pain and, occasionally, loss of smell and taste.

Despite that many reports have established the clinical features of COVID-19 patients, actually, some potential dermatological patterns have been correlated to the disease (maculopapular rashes: 47%, pseudo-chillblain acral lesions: 19%, urticarial lesions: 19%, vesicular eruptions: 9%, livedo or necrosis: 6% of the study sample) 1 .

We present a case of a giant acute urticaria in an infant patient with SARS-CoV-2 positivity, presenting only skin involvement.

A 6-month-old, male infant, whose parents were positive to SARS-CoV-2, underwent polimerase chain reaction (PCR) for COVID-19 by a nasopharyngeal smear test, resulting positive. Although his parents had respiratory symptoms, he was asymptomatic.

Nevertheless, after two weeks, the infant developed a giant urticaria, with multiple lesions, mainly affecting the trunk and limbs (Fig. 1-2 

This article is protected by copyright. All rights reserved.

After conducting an accurate medical history, the disease has not been correlated neither with drugs (topical or systemic), bacterial or parasitic infections, inhalant exposure, or insect bites.

Other allergies such as allergic rhinitis, atopic dermatitis, and food allergy were not reported.

Laboratory findings were within the normal ranges.

Considering the positivity to COVID-19, the diagnostic hypothesis was urticaria triggered by viral infection.

Therefore, the treatment with betamethasone (soluble tablets, 0.5 mg/day for 7 days) led to clinical improvement . After two weeks, a new test for COVID-19 was conducted, resulting negative.

Urticaria occurs quite often in pediatric population, with a prevalence of 3.4% to 5.4% 2 .

Anamnesis and clinical examination are crucial with infant patients, and often reveal an etiology.

The causes of acute urticaria in pediatric subjects differ significantly from those in adults.

Food allergies, viral infections and drug-related causes are predominant in infants, whereas chronic urticaria (CU) is mostly due to physical causes, even though, in most cases, CU in children is spontaneous and no trigger cause is found 3 .

Furthermore, latest reports detected urticaria as a common, prodromal clinical finding among adult COVID-19 patients, with a variable timing of appearance: some lesions appearing before onset of fever, while others 48 hours after 4 .

This article is protected by copyright. All rights reserved. In conclusion, we suggest to consider SARS-CoV-2 infection as a potential cause of urticaria in asymptomatic pediatric patients, uknown carriers of the infection.

In our, lack of maturation of innate and adaptive immune defense mechanisms in infant could explain not only the susceptibility infectious desease, but also the resulting reduced inflammatory response, that provide the absence of systemic symptoms.

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Clinical characteristics of urticaria in children versus adults

First attack of acute urticaria in pediatric emergency department

Urticaria in the times of COVID-19

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Cutaneous manifestations in COVID-19: a first perspective